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Heme oxygenase-1 protects against Alzheimer’s
amyloid-β1-42-induced toxicity via carbon monoxide
production
NT Hettiarachchi1, ML Dallas1,3, MM Al-Owais1, HH Griffiths2,4, NM Hooper2,4, JL Scragg1, JP Boyle1 and C Peers*,1
Heme oxygenase-1 (HO-1), an inducible enzyme up-regulated in Alzheimer’s disease, catabolises heme to biliverdin, Fe2+ and
carbon monoxide (CO). CO can protect neurones from oxidative stress-induced apoptosis by inhibiting Kv2.1 channels, which
mediates cellular K+ efflux as an early step in the apoptotic cascade. Since apoptosis contributes to the neuronal loss
associated with amyloid β peptide (Aβ) toxicity in AD, we investigated the protective effects of HO-1 and CO against Aβ1-42
toxicity in SH-SY5Y cells, employing cells stably transfected with empty vector or expressing the cellular prion protein, PrPc,
and rat primary hippocampal neurons. Aβ1-42 (containing protofibrils) caused a concentration-dependent decrease in cell
viability, attributable at least in part to induction of apoptosis, with the PrPc-expressing cells showing greater susceptibility to
Aβ1-42 toxicity. Pharmacological induction or genetic over-expression of HO-1 significantly ameliorated the effects of Aβ1-42. The
CO-donor CORM-2 protected cells against Aβ1-42 toxicity in a concentration-dependent manner. Electrophysiological studies
revealed no differences in the outward current pre- and post-Aβ1-42 treatment suggesting that K
+ channel activity is unaffected
in these cells. Instead, Aβ toxicity was reduced by the L-type Ca2+ channel blocker nifedipine, and by the CaMKKII inhibitor,
STO-609. Aβ also activated the downstream kinase, AMP-dependent protein kinase (AMPK). CO prevented this activation of
AMPK. Our findings indicate that HO-1 protects against Aβ toxicity via production of CO. Protection does not arise from
inhibition of apoptosis-associated K+ efflux, but rather by inhibition of AMPK activation, which has been recently implicated in
the toxic effects of Aβ. These data provide a novel, beneficial effect of CO which adds to its growing potential as a
therapeutic agent.
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Amongst the earliest of events leading to neuronal loss in
Alzheimer’s disease (AD) is the loss of functional synapses,1–3
apparent long before deposition of amyloid β peptide (Aβ)-
containing plaques.4 Although other parts of the neurone (e.g.
the axon or soma) appear intact, their health at this early stage
of disease progression is not clear. However, neurones
ultimately die in AD and there is clear evidence that numerous
events indicative of apoptosis occur even at early stages of
disease progression.5–8 Thus, targeting of apoptotic mechan-
isms may be of therapeutic value in AD as well as in other
neurodegenerative disorders. Furthermore, apoptosis is
established as a mechanism of neuronal loss following other
types of pathological stresses including ischemia associated
with stroke,9 which can predispose individuals to the devel-
opment of AD.10–12
Apoptosis is strongly influenced by intracellular K+ levels13
which regulate caspase activation, mitochondrial membrane
potential and volume, osmolarity and cell volume.13,14 K+ loss
via K+ channels is a key early stage in apoptosis,15–19 and K+
channel inhibitors can protect against apoptosis triggered by
numerous insults including oxidative stress.20,21 Evidence
suggests a particularly important role for the voltage-gated
channel Kv2.1 in this process: expression of dominant
negative Kv2.1 constructs (thus lacking functional Kv2.1
channels) protects against oxidant-induced apoptosis,
and over-expression of Kv2.1 increases susceptibility to
apoptosis.22,23 Pro-apoptotic agents cause a rapid increase
in the surface expression of Kv2.1 channels,24 but whether
or not this occurs in AD remains to be determined.
Alternative pathways recently reported to promote cell death
include activation of the AMP-dependent protein kinase
(AMP kinase) which can act either as a Tau kinase25 or to
inhibit the mTOR pathway26 and thus contribute to
neurodegeneration.
Heme oxygenases (HO) are enzymes widely distributed
throughout the body. In the central nervous system, HO-2 is
constitutively expressed in neurones and astrocytes, while
HO-1 is inducible in both cell types.27–30 Both HO-1 and HO-2
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break down heme to liberate biliverdin, ferrous iron (Fe2+) and
carbon monoxide (CO). This catalysis is of biological
significance since it is crucial to iron and bile metabolism,
and also generates a highly effective antioxidant in bilirubin
(from biliverdin via bilirubin reductase). Numerous stimuli can
induce HO-1 gene expression,31 including oxidative stress32
and Aβ peptides.33 Importantly, HO-1 is strikingly up-regulated
in AD patients, a finding considered indicative of oxidative
stress.27,34,35 Induction of HO-1 is clearly a neuroprotective
response (although in some cases can exert detrimental
effects27). However, there is growing evidence that CO can be
neuroprotective, for example against the damage of focal
ischemia.36 Our recent studies have demonstrated that CO
provides protection against oxidant-induced apoptosis by
selectively inhibiting Kv2.1.23,37 In the present study, we have
investigated whether HO-1, or its product CO, can provide
protection against Aβ-induced toxicity in the human neuro-
blastoma, SH-SY5Y, and in rat primary hippocampal neu-
rones, andwhether this involves regulation of K+ channels.We
show that both HO-1 and CO protect cells against the toxicity
of protofibrillar Aβ1-42 but that protection does not arise from
inhibition of apoptosis-associated K+ efflux, but rather by
inhibition of AMPK activation.
Results
Aβ(1-42)-induced cell death in SH-SY5Y cells. To investi-
gate any potential role of HO-1 and CO in affording protection
against toxicity induced by Aβ(1-42) (hereafter referred to
simply as Aβ), we first determined their effectiveness in SH-
SY5Y cells either expressing the cellular prion protein (PrPc)
or containing the empty vector, as PrPc is a receptor for
oligomeric38,39 and protofibrillar40 forms of Aβ. Freshly
dissolved Aβ which contained small globular structures
(o10 nm) and Aβ monomers (Figure 1a, upper images)
had no effect on cell viability (not shown). After 24 h
incubation at 37 °C, in addition to the small globular
assemblies and monomers, the Aβ had formed protofibrils
(25–90 nm in length) as assessed by electron microscopy
(Figure 1a, lower images). These structures closely
resembled the nanotubes that have recently been shown to
mediate PrPc-dependent and –independent synaptotoxicity.40
There was no evidence of any amyloid fibrils in our
preparations. Using MTT assays to evaluate cell viability
following exposure to Aβ for 24 h, we found that the
protofibrillar Aβ caused a concentration-dependent loss of
viability, and that cells over-expressing PrPc were significantly
more sensitive to Αβ toxicity than the cells lacking PrPc
Figure 1 Aggregation of Aβ1-42 into protofibrils is toxic to SH-SY5Y cells. (a) Representative images seen by negative stain electron microscopy of globular aggregates seen
in Aβ freshly dissolved in DMEM (0 h, upper images). Boxed area of left-hand image is magnified in right-hand image to show more detail of these structures. Lower images show
globular aggregates plus protofibrillar structures in Aβ solutions stored at 37 oC for 24 h. Boxed area of left-hand image is magnified in right-hand image to show more detail of
these structures. Scale bar in all images 50 nm. (b) Effect of Aβ1-42 on cell viability in SH-SY5Y cells containing empty vector (white bars) and stably expressing PrP
c (gray bars)
using the mitochondrial activity-based MTT assay. Bars represent the mean± S.E.M. data of cells from 10 repeats (each performed in duplicate) with cells from different
passages. (c) The effect of different concentrations of Aβ1-42 (white bars) and the reverse sequence Aβ42-1 (gray bars) on cell viability in empty vector containing and PrP
c-
expressing cells. Bars show the mean± S.E.M. of four repeats. Statistical significance was determined with a one-way ANOVA followed by Bonferroni post-hoc test. ***Po0.001,
#Po0.01. (d) Effect of oxidants on cell viability in empty vector containing (white bars) and PrPc-expressing (gray bars) cells. Left, effect of different concentrations of DTDP
(10 min exposure, left) on cell viability. Each bar represents the mean± S.E.M. of seven repeats. Right, cell viability following a 30 min exposure to various concentrations of
diamide. Each bar shows the mean±S.E.M. of five repeats using cells from different passages. Statistical significance is denoted by **Po0.01, compared to the corresponding
control cells
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(Figure 1b). Extending the incubation period to 48 h did not
increase toxicity further (data not shown). Neither the PrPc-
expressing nor the empty vector containing cells were
significantly affected by the reverse sequence peptide
(Aβ(42-1)) (Figure 1c). Consistent with the idea that PrP
c at
least partly mediates aggregated Αβ toxicity,38–40 over-
expression of PrPc appeared to confer specific sensitivity to
Aβ toxicity, since both the PrPc expressing and empty vector
containing cells were similarly sensitive to the oxidizing
agents dithiodipyridine (DTDP) and diamide (Figure 1d),
both of which have previously been shown to induce
apoptosis.23,37
Aβ-induced cell death is at least partly attributable to
apoptosis. To investigate whether Aβ-induced toxicity arose
from induction of apoptosis, two separate approaches were
taken. The reduction in cell viability caused by Aβ was
significantly reduced by two distinct caspase inhibitors, the
pan-caspase inhibitor (Q-VD-OPh; 1 μM) or the irreversible
caspase inhibitor III (Boc-D-FMK; 10 μM) (Figure 2a), con-
sistent with the idea that Aβ toxicity involves activation of
apoptosis. In both PrPc-expressing cells and empty vector
containing cells, Aβ caused an increase in the proportion of
both CellEvent positive and PI-positive cells (i.e. cells
showing increased caspase activity and loss of viability),
approaching levels seen in cells treated with staurosporine,
which induced positive caspase and PI staining in 80–100%
of cells (Figure 2b). These data further support an important
role for apoptosis induction in the Aβ− induced loss of cell
viability. Using this same assay, we also observed that the
CO-donor, CORM-2, significantly attenuated the number of
CellEvent and PI-positive cells following exposure to 0.5 μM
Aβ (Figure 2b), suggesting a possible protective role for CO
against Aβ toxicity. Importantly, we confirmed this potentially
protective effect of CO in cultured rat primary hippocampal
neurones (Figure 2c). Thus, employing cultures ranging from
7–21 days in vitro, we found that the same protofibrillar
preparation of Aβ at a concentration of 100 nM caused
marked increases in the number of apoptotic cells (indicated
by CellEvent positive cells). Effects were found at all culture
ages, and Aβ was more potent in inducing apoptosis in
hippocampal neurones than in the SH-SY5Y cells
(Figure 2c). In the presence of CORM-2 (10 μM), the effects
of Aβ on hippocampal neurones were largely reversed, and
CORM-2 was without significant effect itself on apoptosis
(Figure 2c). These findings indicate that the neuroprotective
effects of CO against Aβ toxicity can be observed in different
neuronal preparations.
Figure 2 Amyloid toxicity is partly attributable to induction of apoptosis and reversed by CORM-2. (a) Effect on cell viability in empty vector containing (upper) and PrPc-
expressing (lower) cells following 24 h treatment with 0.5 μM Aβ1-42 alone or in the presence of either of two different caspase inhibitors; Q-VD-OPh (1 μM) and caspase inhibitor
III (10 μM), as indicated. Black bars represent untreated cells. Bars indicate mean±S.E.M. of three repeats with cells from different passages for empty vector containing cells
and four repeats for the PrPc-expressing cells. Statistical significance is denoted by ***Po0.001 when compared with the corresponding untreated control and #Po0.001 when
compared with the corresponding Aβ1-42 treated cells. (b) CellEvent positive cells indicate activated caspase 3. Black bars represent the percentage of CellEvent positive cells
and gray bars represent the percentage of PI-positive cells compared with Hoescht positive cells in the area counted. Treatments were for 24 h with the concentrations of drugs
indicated. As a positive control, cells were also treated with 1 μM staurosporine for 10 min and stained with CellEvent and PI. Experiments were performed in triplicate and
repeated with cells from three different passages. Statistical significance is denoted by **Po0.01 and ***Po0.001 when compared with the corresponding untreated cells.
(c) Summary of the CellEvent staining experiments for 7, 14 and 21 day old hippocampal neurons, as indicated. Bars represent the percentage of CellEvent positive cells
compared to the total number of Hoechst positive cells in the area counted. Cells were treated for 24 h with 100 nM Aβ1-42, 100 nM Aβ1-42+10 μM CORM or 10 μM CORM alone,
as indicated. Experiments were performed in triplicate and repeated with cells from three different isolations and shown as mean± S.E.M. Statistical significance is denoted by
***Po0.001 compared with the untreated cells of that specific age group
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HO-1 induction protects against Aβ toxicity. In order to
investigate the ability of HO-1 to protect against Aβ toxicity,
cells were exposed to two established inducers of this
enzyme. Exposure to either 30 μM hemin or 3 μM CoPPIX
for 24 h significantly attenuated the toxic effects of Aβ in both
empty vector containing (Figure 3a) and PrPc-expressing
SH-SY5Y cells (Figure 3b). HO-1 induction was verified by
immunocytochemistry and western blotting in response to
hemin (similar results obtained for CoPPIX; data not shown).
Densitometric analysis indicated that hemin increased HO-1
expression to 188.0±5.0% of control levels (i.e. 1.88-fold;
Po0.001, n= 4 repeats) in empty vector containing cells, and
by 239.5±28.8% (Po0.05, n=4 experiments) in PrPc-
expressing cells. These data suggested that HO-1 affords
protection against Aβ in addition to its known ability to protect
against oxidant-induced apoptosis. To investigate this further,
we over-expressed HO-1 in SH-SY5Y cells. As shown in
Figure 3c, HO-1 over-expression also significantly diminished
the toxic effects of Aβ. Since exposure to Aβ is clearly
deleterious to cells, we also examined whether Aβ itself could
induce expression of HO-1. As shown by western blotting in
Figure 3d, 24 h exposure to Aβ did indeed increase
expression of HO-1 in empty vector and PrPc-expressing
cells, respectively. Interestingly, there was differential sensi-
tivity to Aβ in the two cell groups: For empty vector cells, a
graded increase in HO-1 induction was observed, but in
PrPc-expressing SH-SY5Y cells significant induction was
observed in response to 100 but not 500 nM Aβ. In both cell
groups, induction was modest compared with the effects of
hemin or CoPPIX.
Hypoxia has long been known to induce HO-1
expression,41,42 so we investigated the sensitivity to Αβ of
cells which had been maintained in a hypoxic environment
(0.5% O2, 24 h) prior to (and during) exposure to Aβ. Hypoxia
did indeed induce HO-1 expression, as determined immuno-
cytochemically, and hypoxic cells (both PrPc-expressing and
empty vector containing cells) were significantly more
resistant to the toxic actions of Aβ (Figures 4a and b). This
was particularly prominent in the PrPc-expressing cells. We
therefore used these cells exclusively to examine the ability of
Figure 3 HO-1 protects against Aβ toxicity. (a) Cell viability measured in empty vector containing cells following 24h induction of HO-1 with either 30 μM hemin or 3 μM
CoPPIX in the presence of 500 nM Aβ. Bars indicate mean± S.E.M. of four repeats with cells from different passages. Right (upper) immunofluorescent images of untreated
empty vector containing cells (left) and cells treated with 30 μM hemin (right) for 24 h and then probed using anti-HO-1 primary antibody and DAPI for nuclear staining. Lower;
western blot detection of HO-1 following identical hemin induction. β actin blots are also shown to indicate even loading of protein. (b) As (a) except studies were conducted in
PrPc-expressing cells. (c) Effect of different concentrations of Aβ on empty vector containing cells (black and clear bars) and cells stably over-expressing hHO-1. Bars represent
mean± S.E.M. of six repeats (done in duplicate). (d) Detection of HO-1 induced by Aβ in both cell groups. Upper, example blots from cells exposed either to Aβ42-1 (used as a
control) or Aβ1-42 at the two concentrations indicated in the bar graphs, below. These show mean densitometric analysis of induced expression in empty vector and PrP
c-
expressing cells. Bars represent mean± S.E.M. of four repeats (done in duplicate). Statistical significance is denoted by ***Po0.001 and *Po0.05 when compared with the
corresponding untreated control and #Po0.001 when compared to the corresponding Aβ treated cells
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the HO-1 inhibitor QC-1543 to modulate the responses of
hypoxia-exposed cells to Aβ. As shown in Figure 4c, QC-15
reversed the protective effects of hypoxia against Aβ toxicity,
suggesting strongly that the protective effects of hypoxia were
specifically because of its induction of HO-1.
CO protects against Aβ toxicity: lack of involvement of a
K+ channel ‘surge’. In order to examine whether the
protective effects of HO-1 induction / over-expression could
be attributable to its ability to generate CO (as suggested by
the data presented in Figure 2), we examined the ability of the
CO-donor, CORM-2, to protect cells against Aβ toxicity. In
both empty vector containing cells (Figure 5a) and PrPc-
expressing cells (Figure 5b), exposure of cells to CORM-2
caused a concentration-dependent reduction in the toxic
effects of Aβ. The control compound, iCORM, was without
significant effect, and neither CORM-2 nor iCORM affected
viability when applied alone. These data support the
hypothesis that HO-1 affords protection against Aβ toxicity
via the production (and subsequent action) of CO. In further
support of this hypothesis, we examined the effects of
biliverdin (also produced by HO-1) on Aβ toxicity. As shown
in Figure 5c, exposure of cells to 10 μM biliverdin was without
effect on the toxicity of Aβ in both cell groups, further
supporting the proposal that CO mediates the protective
effects of HO-1 in these cells.
Since exposure of cells to Aβ triggers apoptosis, we
investigated whether this was also associated with increased
K+ channel activity at the plasmamembrane. Previous studies
have shown this is a key event in oxidant-induced apoptotic
cell death,22,44 and we have shown previously that CO is
protective against apoptosis triggered by a K+ channel ‘surge’
(i.e. rapid insertion of channels into the membrane) by
inhibiting the activity of these channels (specifically,
Kv2.123,37). Whole-cell patch-clamp recordings revealed that
K+ current densities, indicative of K+ channel activity at the
plasma membrane, were not significantly affected by expo-
sure to Aβ for 24 h in either the vector only containing cells
(Figure 5d) or in the PrPc-expressing cells (Figure 5e).
However, it was noted that K+ current density was significantly
reduced in PrPc-expressing cells as compared with empty
vector containing cells. The reasons for this are currently
unknown. This notwithstanding, cell death induced by Aβ was
not attributable to the K+ channel ‘surge’ associated with
oxidant-induced apoptosis, indicating that HO-1/CO provided
protection against Aβ toxicity via an alternative mechanism.
Involvement of the CaMKKII/AMPK pathway in Aβ
neurotoxicity. Recent studies have suggested that Aβ
neurotoxicity can involve activation of the Ca2+ /calmodulin
kinase kinase II (CaMKKII)/AMPK pathway.25,26 To investi-
gate the involvement of this pathway in Aβ− induced
neurotoxicity in SH-SY5Y cells as reported here, we first
investigated the effects of suppressing Ca2+ influx into cells
using the L-type Ca2+ channel inhibitor nifedipine. Nifedipine
significantly attenuated Aβ toxicity in both empty vector
containing cells and PrPc-expressing cells (Figure 6a),
suggesting Ca2+ influx via L-type Ca2+ channels is involved
in Aβ toxicity. Since a rise of [Ca2+]i can lead to activation of
CaMKKII, we next explored the involvement of this kinase in
Aβ toxicity, and found that exposure of cells to the CaMKKII
inhibitor STO-609 also significantly attenuated Aβ toxicity
(Figure 6b). Exposure to both nifedipine and STO-609
produced no additional attenuation above that observed by
Figure 4 Protective effect of hypoxia against Aβ toxicity. (a) Effect of hypoxia (48 h, 0.5% O2) on Aβ-induced loss of cell viability in empty vector containing cells. Bars show
mean±S.E.M. of four repeats. Right, immunofluorescent images using anti-HO-1 primary antibody showing upregulation of HO-1 following 48 h of hypoxia. (b) As (a) except
studies were conducted in PrPc-expressing cells. (c) Effects of Aβ on cell viability in hypoxic PrPc-expressing cells in the absence (open bars) and presence (shaded bars) of the
HO-1 inhibitor, QC-15. Bars represent the mean±S.E.M. of four repeats. Statistical significance is denoted by ***Po0.001, #Po0.01 when compared with corresponding
control and corresponding Aβ1-42 treated cells, respectively
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either agent applied alone (data not shown). In agreement
with recent studies, we also found that Aβ activated AMPK,
as demonstrated by a specific increase in the level of AMPK
phosphorylation (without change in total AMPK expression
levels (Figure 7)). In further support of this, we found that Aβ
increased the level of ACC phosphorylation, the major AMPK
substrate. Importantly, CO (applied as CORM-2) prevented
AMPK activation and subsequent phosphorylation of ACC
(Figures 7a and b).
Discussion
The present study aimed to investigate whether HO-1, via CO
generation, provides neuroprotection against the toxicity of Αβ.
There is compelling evidence to suggest that increased HO-1
expression can be neuroprotective against exposure to
glutamate, oxidants or physical damage,27,45 and this protec-
tionmay be attributable, at least in part, to the production of CO
(e.g. Zeynalov et al.36). Although much of the cellular damage
associated with AD is reminiscent of oxidative damage caused
by such agents/interventions, it is important to establish the
specific mechanisms underlying neurodegeneration in AD, in
order to understand any protective actions of HO-1/CO and so,
potentially, exploit such actions in the development of new
anti-neurodegenerative therapies. Indeed, whilst expression
of HO-1 has long been known to be increased in ADpatients,27
it remains to be fully resolved whether this is beneficial or
detrimental. Detrimental effects arising from increased HO-1
expression specifically in glia, have been associated with
excessive deposition of iron as a consequence of increased
heme degradation.46–48 However, other studies suggest
increased astrocytic HO-1 expression can provide protection
for nearby neurons arising specifically from the production
of CO.49
The present study indicates that HO-1 is indeed protective,
and protection appears to arise via the production of CO. Our
study employed SH-SY5Y cells over-expressing PrPc and
demonstrated that such cells were more vulnerable to the
toxicity of Aβwhen compared with the empty vector containing
cells which lack endogenous PrPc expression50 (Figure 1). Aβ
has been show to aggregate and assemble into a range of
dynamic, soluble species, and defining the particular in vivo
‘toxic’ species which correlate most significantly with AD
progression is challenging. PrPc has been identified as a high-
affinity receptor for oligomeric Αβ.38,39,51–53 PrPc is thought to
be a critical mediator of the synaptic loss, neurotoxicity, long-
term potentiation impairments and memory deficits that are
Figure 5 CO protects against Aβ-induced toxicity independently of K+ channel activity. Change in cell viability in empty vector containing (a) and PrPc-expressing (b) cells
following a 24 h treatment with 500 nM Aβ in the absence or presence of various concentrations of the CO-donor CORM-2 (white bars). Also shown is the lack of effect of iCORM
(gray bars) at 30 μM. CORM or iCORMwhen applied alone had no effect on cell viability. Bars represent mean±S.E.M. of six repeats for the empty vector containing cells and 14
repeats for PrPc-expressing cells. Statistical significance is indicated by ***Po0.001, #Po0.01 when compared to the corresponding control and corresponding Aβ1-42 treated
cells, respectively. (c) Change in cell viability in empty vector containing (upper) and PrPc-expressing (lower) cells following a 24 h treatment with 500 nM Aβ in the absence or
presence of 10 mM biliverdin (BV), as indicated. Bars represent the mean±S.E.M. of 4 repeats. (d, e) Mean (± S.E.M., n= 7–9 cells in each case) current density versus
voltage relationships determined in empty vector containing (d) and PrPc-expressing cells (e) with (open symbols) or without (solid symbols) exposure to 1 μM Aβ for 24 h. Inset
shows example families of currents, evoked by step depolarizations (to between −20 and +60 mV) applied from a holding potential of − 70 mV, from which the mean plots were
calculated
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caused by these Aβ oligomers.38,51,52 However, the hetero-
geneity and lack of characterization of the synthetic Aβ
preparations used in some of these studies makes it difficult
to define the active PrPc-dependent Aβ toxic assemblies.
A recent report40 identified protofibrils to be a key PrPc-specific
binding species, defining their triple helical structure as Aβ
nanotubes. These particular structures of Aβ caused PrPc-
dependent synaptotoxicity.40 Electron microscopy indicated
that our preparation of Aβ resembles those used in that
particular study, and thus provide an explanation as to why our
PrPc-expressing cells were selectively more vulnerable to Aβ
toxicity, when their sensitivity to apoptosis induced by oxidants
was similar to that seen in cells lacking PrPc (Figure 1).
Several lines of evidence suggest that HO-1 provided
neuroprotection, reducing the toxic effects of Aβ: thus,
chemical induction of HO-1 with protoporphyrins (Figures 3a
and b) or over-expression of HO-1 (Figure 3c) reduced the
toxic actions of Aβ. Furthermore, protection was provided by
hypoxic induction of HO-1 (Figure 4). Such hypoxic treatment
can alter the expression of many proteins which might
contribute to neuroprotection (see e.g.54 yet this effect of
hypoxia was prevented by the selective HO-1 inhibitor,
QC-15.43 Collectively, these data strongly suggest that HO-1
provides protection against the toxic actions of Aβ. Further-
more, our results also indicate that HO-1 is likely to be
protective because of its ability to generate CO. Thus,
although HO-1 activity was not assessed directly (e.g. via
measurement of CO or bilirubin production) the established
CO-donor, CORM-2 (but not the inactive form, iCORM)
mimicked the effects of HO-1 induction (Figures 2 and 5) to
provide protection against Aβ toxicity. Furthermore, another
HO-1 product, biliverdin, was without protective effect
(Figure 5).
Our previous work has indicated that HO-1, through the
production of CO, protects hippocampal neurons from oxidant-
induced apoptosis by inhibiting the voltage-gated K+ channel
Kv2.1.23 Similarly, HEK293 cells over-expressing Kv2.1
displayed increased vulnerability to oxidant-induced apopto-
sis, and this was also prevented by CO inhibition of Kv2.1.23
Since earlier reports had suggested that toxic effects of Αβ
might arise due to its ability to increase outward K+
currents,55,56 we explored this as a possible mechanism by
which CO might protect SH-SY5Y cells against Aβ toxicity.
Perhaps surprisingly, K+ currents in SH-SY5Y cells were
Figure 6 Aβ toxicity involves Ca2+ influx and CamKKII activation. (a) Cell viability monitored in empty vector containing (left) and PrPc-expressing cells (right) following
exposure to Aβ applied for 24 h either alone or in the additional presence of nifedipine, as indicated. Bar graphs show the mean±S.E.M. of five repeats each for empty vector
containing and PrPc-expressing cells. Statistical significance: ***Po0.001 and #Po0.01 compared to corresponding control and corresponding Aβ1-42 treated cells, respectively.
(b) Cell viability monitored in empty vector containing (left) and PrPc-expressing cells (right) following exposure to Aβ applied for 24 h either alone or in the additional presence of
the CAMKK inhibitor STO-609. Black bars represent the respective untreated cells, clear bars represent cells treated with Aβ and gray bars represent cells treated with Aβ
together with 5 μM STO-609. Bars represent the mean±S.E.M. of four repeats for the empty vector containing and six repeats for the PrPc-expressing cells. Statistical
significance is denoted by ***Po0.001, #Po0.01 when compared with corresponding control and corresponding Aβ1-42 treated cells, respectively
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unaffected by the same levels of Aβ which induced toxicity
(Figure 5). The discrepancy between this finding and earlier
reports on the ability of Aβ to augment K+ currents is not clear
at present, but it is noteworthy that previous studies employed
Aβ at high (410 μM) concentrations,55,56 whereas the present
study largely employed sub-micromolar concentrations of Aβ.
Our results indicate that K+ channel modulation is unlikely to
account for the toxic actions of Aβ and, therefore, the
protective effects of CO. Our data also contrast with an earlier
report that expression of PrPc is associated with augmentation
of K+ currents carried by Kv4.2,57 although we do not know the
contribution of Kv4.2 to whole-cell K+ currents in SH-SY5Y
cells employed here.
In order to explore alternative pathways by which CO might
afford neuroprotection, we first examined the effects of the
L-type Ca2+ channel blocker, nifedipine. Clinical studies have
shown that this class of channel blocker is beneficial in slowing
down the progression of AD,58 and we found nifedipine to
provide significant relief from Aβ toxicity (Figure 6a). This
finding prompted us to investigate potential Ca2+-dependent
pathways associated with Aβ toxicity. Several studies have
implicated AMPK - which can be activated by the Ca2+-
dependent upstream kinase, CaMKKβ - as exerting important
influences on the development of AD. Thus, for example,
Thornton et al.,25 demonstrated that exposure of cortical
neurones to Aβ (20 μM, 30min) activates AMPK in a CaMKKβ-
dependent manner and, importantly, that AMPK subsequently
acts as a Tau kinase, contributing to its hyperphosphorylation.
Yoon et al.26 also reported that Aβ activates AMPK, and
indicated that this led to endoplasmic reticulum stress arising
from inhibition of the mTOR pathway. This in turn led to
activation of JNK3 which, crucially, phosphorylated APP
(amyloid precursor protein). This phosphorylation of APP
promotes its internalization and cleavage to generate
increased levels of Aβ. Most recently, Ca2+ and CaMKKβ-
dependent AMPK activation by Aβ was confirmed in a study
which also demonstrated that activation of the kinase led to a
loss of dendritic spines (an early feature of AD) and also to Tau
phosphorylation.59 Our data indicate that Aβ activates AMPK
in SH-SY5Y cells (Figure 7). Furthermore, this activation is
prevented by CO. The exact site at which CO acts to prevent
AMPK activation, and therefore provide neuroprotection,
remains to be determined. However, this is worthy of further
exploration: despite its deserved reputation as a potent toxin,
the physiological actions of endogenous CO, and its potential
as a therapeutic agent in numerous disorders, is increasingly
being recognized (e.g. Motterlini et al.60). Future studies will
reveal whether it may also be of benefit in combatting
neurodegenerative diseases.
Materials and Methods
Tissue culture. All experiments were conducted using SH-SY5Y cells stably
transfected with either empty pIRESneo vector (BD Biosciences, Oxford, UK;
termed empty vector containing cells in this study) or engineered to express murine
PrPc containing the 3F4 epitope tag (human M108/M111; termed PrPc cells), as
described previously.50 Cells were cultured in DMEM medium containing glutamine,
supplemented with 10% (v/v) fetal calf serum, penicillin (100 U/ml) and streptomycin
(100 U/ml) (all from GIBCO Life Sciences, Paisley, Scotland, UK). Cells were
incubated at 37 °C in a humidified incubator gassed with 95% air and 5% CO2,
passaged every 7 days and used up to 10 passages.
Human HO-1 over-expressing SH-SY5Y cells were generated in-house and
cultured using DMEM media with glutamine, supplemented with 10% (v/v) fetal calf
serum, penicillin (100 U/ml), streptomycin (100 U/ml) (all from GIBCO) and
hygromycin B (200 μg/ml; Calbiochem, Watford, UK). Briefly, SH-SY5Y cells were
transfected with the appropriate pcDNA3.1/human HO-1 construct (Genbank
Accession No.: NM_002133.2) using electroporation (Amaxa - Lonza, Slough, UK)
Figure 7 CO prevents AMPK activation by Aβ. (a) Example western blots showing total and phosphorylated AMPKα, total and phosphorylated acetyl–CoA carboxylase
(ACC) and the corresponding β actin levels in lysates from PrPc-expressing cells. Cells were either untreated, or exposed to Aβ (100 and 500 nM, 24 h), or to 500 nM Aβ in the
additional presence of 20 μM CORM-2, or to CORM-2 alone, as indicated. (b) Mean (± S.E.M., from three experiments) densitometry data under each of the conditions
exemplified in (a). Statistical significance indicated by *Po0.05 when compared with corresponding control and corresponding Aβ1-42 treated cells, respectively
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according to manufacturer’s instructions. Stably transfected cell lines were selected
with hygromycin B antibiotic (200 μg/ml, Calbiochem) added 3 days after transfection.
Selection was applied for 4 weeks (media changed every 4-5 days), colonies were
then picked, grown to confluence and screened by western blotting for HO-1
expression after culturing in T25 flasks for 24–48 h. Hygromycin B selection was
maintained throughout the cloning process at 200 μg/ml and in all subsequent
passages once stable clones had been positively identified.
Primary cultures of hippocampal neurones. Hippocampi of 6–8-day-
old Wistar rats were removed as described previously.39,61 Brain tissue was
incubated with 0.25 μg/ml trypsin for 15 min at 37 °C in phosphate buffered saline
(PBS). Trypsin digestion was terminated by the addition of equal amounts of PBS,
supplemented with 16 μg/ml soybean trypsin inhibitor (type I-S; Sigma, Paisley, UK),
0.5 g/ml DNase I (type II from bovine pancreas; 125 kilounits/ml; Sigma), and
1.5 mM MgSO4. The tissue was then pelleted by centrifugation at 3000 × g for 5 min,
resuspended in 2 ml of PBS with 100 μg/ml soybean trypsin inhibitor, 0.5 μg/ml
DNase I and 1.5 mM MgSO4, triturated gently, and then centrifuged at 3000 × g for
5 min to pellet the hippocampal neurons. The pellet was resuspended in 5 ml of
minimal Earle’s medium supplemented with 10% (v/v) FBS, 13 mM glucose, 50 IU/ml
penicillin, and 50 g/ml streptomycin and added to poly-L-lysine (1.5 mg/ml)-coated
coverslips (0.5 ml/well for 24-well plates). After 24 h, the medium was topped up to
1 ml. After a further 24 h, the culture medium was replaced with one containing
10% (v/v) heat-inactivated horse serum and 80 μM fluorodeoxyuridine to prevent
proliferation of non-neuronal cells. After a further 24 h, the medium was replaced
with serum-free Neurobasal medium, supplemented with 2% (v/v) B27, 50 IU/ml
penicillin, 50 μg/ml streptomycin, 80 μM fluorodeoxyuridine, 25 mM glutamic acid,
and 0.5 mM glutamine.
The cell media used to treat the 7 day cells consisted of neurobasal media
supplemented with penicillin (100 U/ml), streptomycin (100 U/ml), 1% N-2 supple-
ment (to prevent astrocyte growth) and 0.1% Glutamax (all from GIBCO). The media
used for treating the 14 and 21 day cells was free of glutamax as it becomes toxic to
the cells at this stage.
Aβ preparation and assessment. Aβ1-42 and Aβ42-1 (r-Peptides, Bogart,
GA, USA) were dissolved in DMEM (Gibco) to make up 100 μM stock solutions and
kept at − 20 ºC. When needed for experiments one aliquot was maintained at 37 °C
for 24 h to form oligomers prior to treating the cells. EM images were analyzed
using FIJI (ImageJ-2). Briefly, all images were magnified (400%) using Photoshop
CS5.1 (Adobe Systems Inc., Maidenhead, UK) and the longest dimension of all
globular assemblies and protofibrillar structures in each resulting image were
measured after setting the pixel/scale ratio.
Cell viability assays. Cell viability was investigated using thiazolyl blue
tetrazolium bromide (MTT) assays. Cells were cultured in poly-lysine coated 96-
well plates to 450% confluence. The final volume of each well after any
treatment was kept at 100 μl. Cells were treated for 24 h with different
concentrations of either Aβ1-42 or Aβ42-1 dissolved in serum-free culture media.
Likewise, the media in control wells was also replaced with serum-free media for
24 h to ensure that any effects observed were due to Aβ application rather than
serum withdrawal. This was done for all the experiments involving Aβ application.
When applying CORM-2 for 24 h, cells were treated twice per day (9.30am and
5pm). Following 24 h treatments with Aβ and CORM-2, the media was discarded
and the cells gently washed (2x) with PBS to remove all traces of CORM-2, and
so avoid a direct reaction with MTT. PBS was then replaced with 100 μl of fresh
cell culture media in each well. 11 μl of MTT solution (5 mg/ml in sterile PBS,
Sigma) was then added to each well (10% by volume) and the cells incubated at
37 °C for 3 h. Post-incubation, an equal volume (111 μl per well) of solubilizing
solution, consisting of isopropanol and HCl (24 ml propan-1-ol/isopropyl alcohol
(Sigma)+1 ml 1 M HCl), was added to each well to lyse the cells. The contents of
each well were thoroughly mixed by pipetting. Absorbance was measured at
570 nm and at 630 nm using a spectrophotometer. The experiments were
performed in duplicate and repeated using cells from at least 3 different
passages to ensure reliability of the results. All results were normalized to
untreated control cells and shown as a percentage change in cell viability
compared to the corresponding controls.
To determine the proportion of cell death attributable to apoptosis, we employed
the CellEvent staining protocol for both SH-SY5Y cells and hippocampal neurons. For
this, cells were cultured on poly-lysine coated glass coverslips in 6-well plates as
above, and then (after cells reached ca. 50% confluence) treated for 24 h with 500 nM
or 1 μM Aβ1-42, Aβ1-42+CORM-2, or staurosporine (applied at 1 μM for 10 min).
Following treatment, cell media was discarded and the CellEvent dye (8 μM in PBS,
Invitrogen, Paisley, UK) applied for 30 min in the dark at 37 ºC. Thereafter, following a
rapid wash, cells were incubated with propidium iodide (500 nM, Invitrogen) for 5 min.
Coverlips were washed again with PBS prior to applying 2 drops of Hoechst 33342
solution (Invitrogen) to 1 ml of PBS in each well, and then incubated for 20 min in the
dark in order to stain nuclei. After further washing (3 × 5min in the dark), cells were
fixed with 4% paraformaldehyde for 20 min, then washed gently with PBS and the
coverslips mounted on slides using mounting medium (VectashieldR, Vector
Laboratories, Peterborough, UK). The coverslips were sealed and examined using
a Nikon E600 light microscope (Nikon, Kingston upon Thames, UK). All the images
were obtained using the x40 lens and Q imaging micropublisher ACQuis
(Syncroscopy, Cambridge, UK) software. At least three fields of interest were taken
for each slide, and the number of cells with Hoechst positive nuclei that also stained
positive for CellEvent or PI were counted. The data is presented as a percentage of
(+) CellEvent or PI stained cells compared to the corresponding Hoechst (+) cells.
Hippocampal neurones were cultured on poly-lysine coated coverslips for 7, 14
or 21 days. On the specific days, the coverslips were washed twice with sterile PBS
twice to get rid of cell debris and the cells were then treated for 24 h with fresh
media for the control cells or media containing 100 nM Aβ1-42, 10 μM CORM or
100 nM Aβ1-42+10 μM CORM. Following the 24 h incubation period, the cells were
stained with the CellEvent dye and examined and analyzed exactly as for
SH-SY5Y cells.
Immunocytochemistry. Cells were cultured on poly-lysine coated glass
coverslips in 6-well plates at450% confluence prior to treatment with either 3 μM
cobalt protoporphyrin (CoPPIX) or 30 μM chloroferriprotoporphyrin (hemin;
Calbiochem) for 24 h, or prior to exposure to hypoxia (0.5% O2, 48 h). Following
said treatments, cells were immunostained for HO-1. Briefly, media was discarded
and the cells were washed (3 × 5min) with Dulbecco’s PBS. Cells were then fixed
with parafomaldehyde (4% in PBS) for 20 min, following which they were
permeabilized with PBS containing 0.22% Triton X100 supplemented with 10%
normal goat serum (NGS; Sigma). Following 3 × 5 min washes with Dulbecco’s PBS
containing 1% NGS, cells were then incubated overnight at 4 °C with the primary
antibody; rabbit polyclonal anti-HO-1 (1 : 100, Santa Cruz, Heidelburg, Germany) in
Dulbecco’s PBS containing 1% NGS. The following day, cells were washed with
Dulbecco’s PBS containing 1% NGS (3 × 5 min). Antibody binding was visualized
by incubating the cells with a secondary antibody; Alexa Fluor-488 conjugated
anti-rabbit IgG (1 : 1000, Invitrogen), for 1h in the dark. Post-incubation, and
following 3 × 5 min washes with Dulbecco’s PBS, coverslips were mounted on
slides using VectashieldR mounting media containing DAPI (Vector Laboratories).
The slides were then examined using a Zeiss (Cambridge, UK) laser scanning
confocal microscope (LSM 510).
Electrophysiology. Fragments of coverslip with attached cells were
transferred to a continuously perfused (3–5 ml/min) recording chamber mounted
on the stage of an Olympus (Southend, UK) CK40 inverted microscope. All
experiments were carried out at 22± 1 °C, unless otherwise stated. Cells were
continually perfused with a solution containing (in mM): 135 NaCl, 5 KCl, 1.2 MgCl2,
5 HEPES, 2.5 CaCl2, 10 D-glucose (pH 7.4 with NaOH). Whole-cell patch-clamp
recordings were then obtained in voltage-clamp mode with cells clamped at
− 70 mV. Patch pipettes had resistances 4-6 MΩ when filled with an intracellular
solution consisting of (in mM): 10 NaCl, 117 KCl, 2 MgCl2, 11 HEPES, 11 EGTA, 1
CaCl2, 2 Na2ATP (pH 7.2 with KOH). After breaking into the whole-cell configuration,
series resistance was monitored throughout the duration of experiments. If a
significant increase occurred (420%), the experiment was terminated. Signals
were acquired using a Axopatch 200B (Axon Instruments Inc., Foster City, CA,
USA) controlled by Clampex 9.0 software via a Digidata 1322A interface (Axon
Instruments Inc.). Data were filtered at 1 kHz and digitized at 2 kHz. To evoke ionic
outward K+ currents in SHSY5Y cells, a series of 100 ms depolarizing steps from
− 80 to +60 mV, in 10 mV increments, were employed. Offline analysis was carried
out using the data analysis package Clampfit 9 (Axon Instruments) and data are
expressed as mean± S.E.M.
Western blotting. Cells used for immunoblotting were cultured in T25 flasks
and when confluent, washed in PBS and then lysed in situ with 200 μl of
mammalian protein extraction reagent (M-PER, Pierce, Loughborough, UK)
containing complete protease inhibitor tablets (Roche) for 30 min at room
temperature. Protein levels in the lysates were assessed using a BCA assay
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(Pierce). Cell proteins (typically 30 μg protein per lane) were separated on 12.5%,
0.75 mm thick polyacrylamide SDS gels and electrophoretically transferred to
0.2 μm PVDF membranes (BioRad). The blots were probed with primary antibodies
(1 : 1000, cell signaling) raised against AMPKα, phospho-AMPKα, Acetyl-CoA
Carboxylase (ACC), Phospho-acetyl-CoA Carboxylase (phospho-ACC) at room
temperature for 3 h or HO-1 (1 : 200, Santa Cruz) at 4 °C overnight. Next,
membranes were washed with PBS for 30 min prior to incubating with the
appropriate anti-rabbit or anti-mouse horse radish peroxidise-conjugated secondary
antibody (1 : 2000; Amersham Pharmacia Biotech, Buckinghamshire, UK) for 1 h at
room temperature. Following this incubation, membranes were washed in PBS for
30 min and bands visualized using an enhanced chemiluminescence detection
system and hyperfilm ECL (Merck, UK).
Statistical analysis. Data are shown as mean± S.E.M. Statistical analysis
was carried out using one-way ANOVA followed by either the Dunnett’s or
Bonferroni post-test, as appropriate. P values of less than 0.05 were considered
significant. CellEvent results were analyzed using a two-way ANOVA followed by a
Bonferroni post-test. Po0.05 was considered to be significant.
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